



# MEDICAL EXAMINATION REPORT (MER)

If the examinee is suffering from an acute life threatening situation, you may be obliged to disclose the result of the medical examination to the examinee.

1.	Name of the examinee	:	Mr./Mrs./Ms. DEEPU SEBASTIAN EDMOND
2.	Mark of Identification	Tinke.	(Mole/Scar/any other (specify location)):
_3.	Age/Date of Birth	:	35, 25-09-1987 Gender: F/M
4.	Photo ID Checked	:	(Passport/Election Card/PAN Card/Driving Licence/Company ID) (

## PHYSICAL DETAILS:

a. Height	b. Weight	c. Girth of Abdomenl.o.7 (cms)  Systolic   30 Diastolic & O	
	1st Reading	Total gailest	
	2 <sup>nd</sup> Reading	eta secala magazarani luvulla nuovan basul	

#### FAMILY HISTORY:

Relation	Age if Living	Health Status	If deceased, age at the time and cause
Father		1	
Mother			
Brother(s)		/ NC	
Sister(s)		III) (or employ) (em.	to you think needed as MEDICALLY FIT or USE

HABITS & ADDICTIONS: Does the examinee consume any of the following?

Tobacco in any form	Sedative	ASALID BE 23 Alcohol X3 JAO16
his/her ideality and the finances are	above individual after-verification of	by coalirm that I be examined the

# PERSONAL HISTORY

- a. Are you presently in good health and entirely free from any mental or Physical impairment or deformity.
   If No, please attach details.
- b. Have you undergone/been advised any surgical procedure?
- c. During the last 5 years have you been medically examined, received any advice or treatment or admitted to any hospital?
- d. Have you lost or gained weight in past 12 months?


# Have you ever suffered from any of the following?

- Psychological Disorders or any kind of disorders of the Nervous System?
- · Any disorders of Respiratory system?
- · Any Cardiac or Circulatory Disorders?
- Enlarged glands or any form of Cancer/Tumour?
- · Any Musculoskeletal disorder?

- · Any disorder of Gastrointestinal System?
- Unexplained recurrent or persistent fever, and/or weight loss
- Have you been tested for HIV/HBsAg / HCV before? If yes attach reports
- · Are you presently taking medication of any kind?







YON


Corp. Office: DDRC SRL Tower, G- 131, Panampilly Nagar, Ernakulam - 682 036 Ph No. 0484-2318223, 2318222, e-mail: info@ddrcsrl.com, web: www.ddrcsrl.com

<ul> <li>Any disorders of Urinary System?</li> </ul>	YN	<ul> <li>Any disorder of the Eyes, Ears, Nose, Throat Mouth &amp; Skin</li> </ul>	or YN
FOR FEMALE CANDIDATES ONLY NA			
a. Is there any history of diseases of breast/genital organs?	Y/N	d. Do you have any history of miscarriage/ abortion or MTP	Y/N
<ul> <li>b. Is there any history of abnormal PAP Smear/Mammogram/USG of Pelvis or any other tests? (If yes attach reports)</li> </ul>			
c. Do you suspect any disease of Uterus, Cervix or Ovaries?	Y/N	f. Are you now pregnant? If yes, how many mo	onths? Y/N
CONFIDENTAIL COMMENTS FROM MEDICA	AL EXA	MINER	
➤ Was the examinee co-operative?	ne ed	Part of the same o	CYN
Is there anything about the examine's health, life his/her job?	style tha	t might affect him/her in the near future with reg	ard to
> Are there any points on which you suggest further	er inform	nation be obtained?	Y/N
> Based on your clinical impression, please provid	e your st	uggestions and recommendations below;	
Me	dice	Mouth & Skin  Do you have any history of miscarriage/ abortion or MTP  Y/N  For Parous Women, were there any complication during pregnancy such as gestational diabetes, hypertension etc  Y/N  Are you now pregnant? If yes, how many months?  Y/N  NER  Ight affect him/her in the near future with regard to  Y/N  on be obtained?  Postions and recommendations below;	
			anile :
		V	
> Do you think he/she is MEDICALLY FIT or UN	FIT for e	employment.	
	CIT		
	FIL		
MEDICAL EXAMINER'S DECLARATION			
I hereby confirm that I have examined the above indivabove are true and correct to the best of my knowledge		ter verification of his/her identity and the finding	gs stated
		A BOMERN T	
All the of early one part of our	20 %	55% declaration in officers of some a	
Name & Signature of the Medical Examiner	7		
	D= 0	SEOROE -	
Seal of Medical Examiner :	Di. G	MD FCSI FIAE	
	MED	JICAL EXAMINER	
	[55]	Reg: 86614	
Name & Seal of DDRC SRL Branch :		GNOS	
	/	TOWN OF THE REAL PROPERTY OF THE PERSON OF T	
D to 0 Times		ST KADAVII BURUMANSI E	
Date & Time :		1710112033	
		1.0/	C
		10CH1-36	

# **DDRC SRL** Diagnostics Private Limited

Corp. Office: DDRC SRL Tower, G- 131, Panampilly Nagar, Ernakulam - 682 036 Ph No. 0484-2318223, 2318222, e-mail: info@ddrcsrl.com, web: www.ddrcsrl.com







Mr. Deepu Sebastian Edmond 35/ Male

Mediwheel Arcofemi Heelthcare Limited

Date - 11/03/2023

Acc. No. 4126WC003747

Treadmill test not done

DDRCSRL







CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESSY THE ARE LIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334 Email: customercare.ddrc@srl.in

DEEPM1103884126

PATIENT ID :

ABHA NO:

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

**Test Report Status** 

DRAWN:

**Final** 

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

ACCESSION NO: 4126WC003747 AGE: 35 Years

Results

RECEIVED: 11/03/2023 09:34

SEX: Male

Biological Reference Interval Units

MEDIWHEEL HEALTH CHEKUP BELOW 40(M)TMT

TREADMILL TEST

TREADMILL TEST

CANCELLED

Scan to View Details

Page 1 Of 15 Scan to View Report

CIN: U85190MH2006PTC161480





CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS ! TU

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

Results

PATIENT ID :

DEEPM1103884126

Units

DRAWN:

RECEIVED: 11/03/2023 09:34

ABHA NO :

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID:

**Final** 

MEDIWHEEL HEALTH CHEKUP BELOW 40(M)TMT

**Test Report Status** 

**BUN/CREAT RATIO BUN/CREAT RATIO** 

17.3

CREATININE, SERUM

CREATININE

1.04

18 - 60 yrs : 0.9 - 1.3

mg/dL

METHOD : JAFFE KINETIC METHOD

GLUCOSE, POST-PRANDIAL, PLASMA

GLUCOSE, POST-PRANDIAL, PLASMA

94

Diabetes Mellitus : > or = 200.

mg/dL

Impaired Glucose tolerance/ Prediabetes: 140 - 199. Hypoglycemia: < 55.

METHOD : HEXOKINASE

GLUCOSE FASTING, FLUORIDE PLASMA

GLUCOSE, FASTING, PLASMA

80

5.0

Diabetes Mellitus : > or = 126.

mg/dL

Impaired fasting Glucose/ Prediabetes: 101 - 125. Hypoglycemia : < 55.

METHOD : HEXOKINASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD** 

GLYCOSYLATED HEMOGLOBIN (HBA1C)

Normal

: 4.0 - 5.6%. %

Non-diabetic level : < 5.7%.

Diabetic

: >6.5%

Glycemic control goal

More stringent goal : < 6.5 %.

General goal

: < 7%. Less stringent goal : < 8%.

Glycemic targets in CKD :-

If eGFR > 60 : < 7%

If eGFR < 60: 7 - 8.5%. < 116.0

96.8

mg/dL

LIPID PROFILE, SERUM

MEAN PLASMA GLUCOSE

High Desirable : < 200

CHOLESTEROL

242

Borderline: 200-239 High : >or= 240 mg/dL

METHOD : CHOD-POD

Scan to View Details

Page 2 Of 15 Scan to View Report

CIN: U85190MH2006PTC161480

DRAWN:



CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESSY THE ADELIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156



DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

RECEIVED: 11/03/2023 09:34

PATIENT ID : DEEPM1103884126

ABHA NO :

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Units
TRIGLYCERIDES	160	High Normal : < 150 High : 150-199 Hypertriglyceridemia : 200-49	mg/dL
HDL CHOLESTEROL METHOD: DIRECT ENZYME CLEARANCE	38	Very High: > 499 Low General range: 40-60	mg/dL
DIRECT LDL CHOLESTEROL	173	High Optimum : < 100 Above Optimum : 100-139 Borderline High : 130-159 High : 160-189 Very High : >or= 190	mg/dL
NON HDL CHOLESTEROL	204	High Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
ERY LOW DENSITY LIPOPROTEIN	32.0	Desirable value :	mg/dL
CHOL/HDL RATIO	6.4	10 - 35 High 3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk	
DL/HDL RATIO	4.6	> 11.0 High Risk  High 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate R >6.0 High Risk	isk







CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESSY THE

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID .

DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

ABHA NO:

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED :

11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

**Test Report Status** 

**Final** 

Results

Units

#### Interpretation(s)

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

# Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Extreme risk group	A.CAD with > 1 feature of high risk group  B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C  or = 50 mg/dl or polyvascular disease		
Very High Risk	Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.     Familial Homozygous Hypercholesterolemia		
High Risk	Three major ASCVD risk factors. 2. I organ damage. 3. CKD stage 3B or 4. 4.	Diabetes with 1 major risk factor or no evidence of end LDL>190 mg/dl 5. Extreme of a single risk factor. 6. J. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid	
	piaque	5 Tota stenotic carolin	
Moderate Risk		g a strong genotic carolic	
Low Risk	2 major ASCVD risk factors 0-1 major ASCVD risk factors		
Low Risk Major ASCVD (Ath	2 major ASCVD risk factors 0-1 major ASCVD risk factors erosclerotic cardiovascular disease) Pick		
Low Risk Major ASCVD (Ath	2 major ASCVD risk factors 0-1 major ASCVD risk factors erosclerotic cardiovascular disease) Pick	Factors	
Low Risk Major ASCVD (Ath	2 major ASCVD risk factors 0-1 major ASCVD risk factors erosclerotic cardiovascular disease) Risk is in males and > or = 55 years in females.		

in initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-UDI (/-ID		
	DEE C (mg/ui)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)



Page 4 Of 15 Scan to View Report

CIN: U85190MH2006PTC161480

DRAWN:

**Test Report Status** 





DEEPM1103884126

Units

CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS ! TUCADE

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

**Final** 

PATIENT ID :

Results

ACCESSION NO: 4126WC003747 AGE: 35 Years SEX: Male

ABHA NO :

RECEIVED: 11/03/2023 09:34 REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID:

Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <or 60)<="" =="" th=""><th>&gt;OR = 50</th><th>&gt;OR = 80</th></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	00 10	
High Risk	<70		>OR= 50	>OR= 80
Moderate Risk	<100	<100	>OR= 70	>OR= 100
Low Risk		<130	>OR= 100	>OR= 130
	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

# LIVER FUNCTION TEST WITH GGT

BILIRUBIN, TOTAL METHOD: DIAZO METHOD	0.37	General Range : < 1.1	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO METHOD	0.15	General Range : < 0.3	mg/dL
BILIRUBIN, INDIRECT	0.22	0.00 - 0.60	mg/dL
TOTAL PROTEIN	7.6	Ambulatory: 6.4 - 8.3	g/dL
ALBUMIN GLOBULIN	4.6	Recumbant : 6 - 7.8 20-60yrs : 3.5 - 5.2	g/dL
	3.0	2.0 - 4.0 Neonates - Pre Mature:	g/dL
ALBUMIN/GLOBULIN RATIO	1.5	0.29 - 1.04 1.00 - 2.00	DATTO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26	Adults : < 40	RATIO U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: IFCC WITHOUT PDP	56	Adults : < 45	U/L
ALKALINE PHOSPHATASE METHOD: IFCC	70	Adult(<60yrs) : 40 -130	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) TOTAL PROTEIN, SERUM	45	Adult (Male) : < 60	U/L
TOTAL PROTEIN	7.6	Ambulatory: 6.4 - 8.3	55440
METHOD : BIURET	710	Recumbant : 6 - 7.8	g/dL
URIC ACID, SERUM			
URIC ACID	7.0	Adults: 3.4-7	mg/dL









CLIENT'S NAME AND ADDRESSY THORSE INTER

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334 Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

ACCESSION NO: 4126WC003747 AGE: 35 Years

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

SEX: Male

PATIENT ID : DEEPM1103884126

DRAWN:

ABHA NO:

RECEIVED: 11/03/2023 09:34

REPORTED: 11/03/2023 17:04

CLIENT PATIENT ID:

**Test Report Status Final** Units

			Units
METHOD : SPECTROPHOTOMETRY			
ABO GROUP & RH TYPE, EDTA WHOLE BLO	OD		
ABO GROUP METHOD: GEL CARD METHOD	TYPE A		
RH TYPE	POSITIVE		
BLOOD COUNTS, EDTA WHOLE BLOOD	. 5511112		
HEMOGLOBIN METHOD: NON CYANMETHEMOGLOBIN	14.7	13.0 - 17.0	g/dL
RED BLOOD CELL COUNT . METHOD: IMPEDANCE	4.87	4.5 - 5.5	mil/μL
WHITE BLOOD CELL COUNT METHOD: IMPEDANCE	6.07	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: IMPEDANCE	254	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT METHOD: CALCULATED	43.6	40 - 50	%
MEAN CORPUSCULAR VOL METHOD: DERIVED FROM IMPEDANCE MEASURE	89.4	83 - 101	, fL
MEAN CORPUSCULAR HGB.  METHOD: CALCULATED	30.3	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED	33.8	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH	14.1	12.0 - 18.0	
MENTZER INDEX	18.4	12.0 - 10.0	%
MEAN PLATELET VOLUME	9.1	6.8 - 10.9	fL
METHOD : DERIVED FROM IMPEDANCE MEASURE WBC DIFFERENTIAL COUNT			
SEGMENTED NEUTROPHILS  METHOD: DHSS FLOWCYTOMETRY	46	40 - 80	%
LYMPHOCYTES METHOD: DHSS FLOWCYTOMETRY	43	High 20 - 40	%
MONOCYTES  METHOD: DHSS FLOWCYTOMETRY	8	2 - 10	%
EOSINOPHILS METHOD: DHSS FLOWCYTOMETRY	3	1 - 6	. %









DEEPM1103884126

CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESSY THE ADD I MITTED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334 Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

ACCESSION NO: 4126WC003747 AGE: 35 Years SEX: Male

ABHA NO:

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED: 11/03/2023 17:04

PATIENT ID :

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED


CLIENT PATIENT ID :

Test Report Status <u>Final</u>	Results		Units
BASOPHILS METHOD: IMPEDANCE	0	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED	2.79	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED	2.61	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED	0.49	0.20 - 1,00	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED	0.18	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT NEUTROPHIL LYMPHOCYTE RATIO (NLR) ERYTHROCYTE SEDIMENTATION RATE (ESR),W	0.00 1.1 /HOLE	0.00 - 0.10	thou/µL
SEDIMENTATION RATE (ESR) METHOD: WESTERGREN METHOD	07	0 - 14	mm at 1 hr
SUGAR URINE - POST PRANDIAL SUGAR URINE - POST PRANDIAL THYROID PANEL, SERUM	NOT DETECTED	NOT DETECTED	
METHOD: ELECTROCHEMILUMINESCENCE	120.80	80 - 200	ng/dL
4 METHOD: ELECTROCHEMILUMINESCENCE	7.98	5.1 - 14.1	μg/dl
SH 3RD GENERATION  METHOD : ELECTROCHEMILUMINESCENCE	1.530	21-50 yrs : 0.4 - 4.2	μIU/mL









CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESSY THE ARE LIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID : DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE:

SEX: Male

ABHA NO :

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

**Test Report Status** 

Final

Results

Units

#### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituters advance (2) TDI
7	Low	Low	Low	Low	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m.

# PHYSICAL EXAMINATION, URINE

COLOR AMBER **APPEARANCE** CLEAR CHEMICAL EXAMINATION, URINE

5.0

4.8 - 7.4











CLIENT CODE: CA00010147 - MEDIWHEEL
CLIENT'S NAME AND ADDRESS! THOMES INVESTED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156 DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

ACCESSION NO: 4126WC003747 AGE: 35 Years

Years SEX : Male

ABHA NO :

DEEPM1103884126

DRAWN:

RECEIVED: 11/03/2023 09:34

A CONTRACTOR OF THE PARTY OF TH

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

PATIENT ID:

Test Report Status <u>Final</u>	Results		Units
CDECIFIC OR WITH	-		
SPECIFIC GRAVITY	1.025	1.015 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
JROBILINOGEN	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
VBC	1-2	0-5	/HPF
PITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED		/1111
RYSTALS	NOT DETECTED		
ACTERIA	NOT DETECTED	NOT DETECTED	
EAST	NOT DETECTED	NOT DETECTED	









CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESSY THE ARE LIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID :

DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

ABHA NO :

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

**Test Report Status** 

**Final** 

Results

Units

## Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination b genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenou infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Jric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

D UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN METHOD : UREASE - UV

18

Adult(<60 yrs): 6 to 20

mg/dL

SUGAR URINE - FASTING

SUGAR URINE - FASTING PHYSICAL EXAMINATION, STOOL

NOT DETECTED

NOT DETECTED

COLOUR

BROWN


CONSISTENCY

WELL FORMED

Page 10 Of 15 Scan to View Report

CIN: U85190MH2006PTC161480







CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS ! THE ADE LIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131,Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email : customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID :

DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

ABHA NO :

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED: 11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status <u>Final</u>	Results		Units
MUCUS VISIBLE BLOOD ADULT PARASITE MICROSCOPIC EXAMINATION, STOOL	NOT DETECTED ABSENT NOT DETECTED	NOT DETECTED ABSENT	
PUS CELLS RED BLOOD CELLS CYSTS OVA	0-1 NOT DETECTED NOT DETECTED NOT DETECTED	NOT DETECTED	/hpf · /HPF
LARVAE TROPHOZOITES FAT VEGETABLE CELLS CHARCOT LEYDEN CRYSTALS	NOT DETECTED NOT DETECTED ABSENT ABSENT ABSENT	NOT DETECTED  NOT DETECTED	









CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS ! TUCARE I TANTED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID:

DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

ABHA NO :

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED:

11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID:

**Test Report Status** 

**Final** 

Results

Units

#### Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

### ADDITIONAL STOOL TESTS:

- Stool Culture: This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3. 4.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus ,parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.

Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery



Page 12 Of 15 Scan to View Report

CIN: U85190MH2006PTC161480





CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS! TUCARE

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID :

DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

ABHA NO .

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED :

11/03/2023 17:04

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

**Test Report Status** 

Final

Results

Units

diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Interpretation(s)
CREATININE, SERUM-Higher than normal level may be due to:
Blockage in the urinary tract

Blockage in the unnary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
 Muscle problems, such as breakdown of muscle fibers
 Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Myasthenia Gravis

Mysstnenia Gravis
 Muscular dystrophy
 GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in Pancreased in Pancreased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic Index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

HbA1c Estimation can get affected due to :

HbA1c Estimation can get affected due to:
I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower that c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
III.Iron deficiency anemia is reported to increase test results. (possibly by inhibiting glycation of hemoglobin.
IIII.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum...Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''''''s disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic



Page 13 Of 15 Scan to View Report

CIN: U85190MH2006PTC161480







CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND YDORESSY

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID : DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

SEX: Male

ABHA NO :

DRAWN:

RECEIVED: 11/03/2023 09:34

REPORTED: 11/03/2023 17:04

CLIENT PATIENT ID :

**Test Report Status** 

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

Final

Results

Units

syndrome, Protein-losing enteropathy etc. URIC ACID, SERUM-Causes of Increase sed levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome

Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD
Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4 to 1.5 years old and NLR = 3.5 years ol

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

SUGAR URINE - POST PRANDIAL-METHOD: DIPSTICK/BENEDICT"S TEST

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

SUGAR URINE - FASTING-METHOD: DIPSTICK/BENEDICT'S TEST

to View Details

Page 14 Of 15 回旅游通 Scan to View Report

CIN: U85190MH2006PTC161480







CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS! TUCADE

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. DEEPU SEBASTIAN EDMOND

PATIENT ID :

DEEPM1103884126

ACCESSION NO: 4126WC003747 AGE: 35 Years

REFERRING DOCTOR: DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

SEX: Male

ABHA NO:

DRAWN:

REPORTED: 11/03/2023 17:04

RECEIVED: 11/03/2023 09:34

CLIENT PATIENT ID :

**Test Report Status** 

**Final** 

Results

Units

# MEDIWHEEL HEALTH CHEKUP BELOW 40(M)TMT

**ECG WITH REPORT** 

REPORT

TEST COMPLETED

USG ABDOMEN AND PELVIS

TEST COMPLETED

**CHEST X-RAY WITH REPORT** 

REPORT

TEST COMPLETED

\*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

ANCY ABRAHAM, MSC MICROBIOLOGY Senior Microbiologist

DR.HARI SHANKAR, MBBS MD (Reg No - TCMC:62092) HEAD - Biochemistry & Immunology


DR. VIJAY K N, MBBS MD(PATH) (Reg No - KMC:91816) **HEAD-HAEMATOLOGY & CLINICAL PATHOLOGY** 

Dr.ASWATHY VARGHESE, MBBS, MD(MICROBIOLOGY) (Reg No - TCMC:50839) CONSULTANT MICROBIOLOGIST





CIN: U85190MH2006PTC161480





NAME: MR DEEPU SEBASTIAN EDMOND	STUDY DATE 11/03/2023	
AGE / SEX :35 YRS / M	REPORTING DATE:11/03/2023	
REFERRED BY : MEDIWHEEL	ACC NO: 4126WC003747	

# X - RAY - CHEST PA VIEW

- > Both the lung fields are clear.
- B/L hila and mediastinal shadows are normal.
- Cardiac silhouette appears normal.
- Cardio thoracic ratio is normal.
- Bilateral CP angles and domes of diaphragm appear normal.

IMPRESSION: NORMAL STUDY

Kindly correlate clinically

Dr. NAVNEET KAUR, MBBS,MD Consultant Radiologist.





Date...11..03...2023

# **OPHTHALMOLOGY REPORT**

	fy that I have examined	
visual standard	ds is as follows :	
Visual Acuity:	the state of the s	
For far vision	R:	
For near vision	R:	
For near vision	L:	
Color Vision :	Normal	
******	GNOST	
	Nannu Elizabeth	59UT. LT

(Optometrist)



NAME	MR DEEPU SEBASTAIN EDMOND	AGE	35 YRS
SEX	MALE	DATE	March 11, 2023
-	MEDIWHEEL ARCOFEMI	ACC NO	4126WC003747

# **USG ABDOMEN AND PELVIS**

LIVER

Measures ~ 15.4 cm. Bright echotexture.

Smooth margins and no obvious focal lesion within. No IHBR dilatation. Portal vein normal in caliber.

GB

Contracted.

SPLEEN

Measures ~ 9.8 cm, normal to visualized extent. Splenic vein normal.

PANCREAS

Normal to visualized extent. PD is not dilated.

KIDNEYS

RK: 11.2 x 4.1cm, appears normal in size and echotexture

LK: 10.6 x 4.7 cm, appears normal in size and echotexture.

No focal lesion / calculus within.

Maintained corticomedullary differentiation and normal parenchymal thickness.

No hydroureteronephrosis.

BLADDER

Normal wall caliber, no internal echoes/calculus within.

PROSTATE

Normal in volume and echopattern.

NODES/FLUID

Nil to visualized extent.

BOWEL

Visualized bowel loops appear normal.

**IMPRESSION** 

Hepatomegaly with grade I/II fatty liver.

Kindly correlate clinically.

Dr. NAVNEET KAUR MBBS . MD

**Consultant Radiologist** 

Thank you for referral. Your feedback will be appreciated.

CIN: U85190MH2006PTC161480







